139 related articles for article (PubMed ID: 21397305)
1. Low-grade serous primary peritoneal carcinoma.
Schmeler KM; Sun CC; Malpica A; Deavers MT; Bodurka DC; Gershenson DM
Gynecol Oncol; 2011 Jun; 121(3):482-6. PubMed ID: 21397305
[TBL] [Abstract][Full Text] [Related]
2. Papillary serous carcinoma in ovaries of normal size: a clinicopathologic study of 20 cases and comparison with extraovarian peritoneal papillary serous carcinoma.
Choi CH; Kim TJ; Kim WY; Ahn GH; Lee JW; Kim BG; Lee JH; Bae DS
Gynecol Oncol; 2007 Jun; 105(3):762-8. PubMed ID: 17383715
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
Schmeler KM; Sun CC; Bodurka DC; Deavers MT; Malpica A; Coleman RL; Ramirez PT; Gershenson DM
Gynecol Oncol; 2008 Mar; 108(3):510-4. PubMed ID: 18155273
[TBL] [Abstract][Full Text] [Related]
4. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
[TBL] [Abstract][Full Text] [Related]
5. Ovarian serous borderline tumors with invasive peritoneal implants.
Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
[TBL] [Abstract][Full Text] [Related]
6. "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer.
Seidman JD; Zhao P; Yemelyanova A
Gynecol Oncol; 2011 Mar; 120(3):470-3. PubMed ID: 21159368
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of clinical characteristics of extraovarian peritoneal serous papillary carcinoma with papillary serous ovarian carcinoma].
Peng YZ; Shen K; Wu M; Huang HF; Pan LY; Yang JX; Lang JH
Zhonghua Fu Chan Ke Za Zhi; 2005 Apr; 40(4):243-5. PubMed ID: 15924670
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
9. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum.
Seidman JD; Horkayne-Szakaly I; Cosin JA; Ryu HS; Haiba M; Boice CR; Yemelyanova AV
Gynecol Oncol; 2006 Nov; 103(2):703-8. PubMed ID: 16828848
[TBL] [Abstract][Full Text] [Related]
10. Are all pelvic (nonuterine) serous carcinomas of tubal origin?
Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R
Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711
[TBL] [Abstract][Full Text] [Related]
11. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.
Dubernard G; Morice P; Rey A; Camatte S; Fourchotte V; Thoury A; Pomel C; Pautier P; Lhommé C; Duvillard P; Castaigne D
Eur J Surg Oncol; 2004 Nov; 30(9):976-81. PubMed ID: 15498644
[TBL] [Abstract][Full Text] [Related]
12. Ovarian serous cystadenofibromas associated with a low-grade serous carcinoma of the peritoneum.
Hinson SA; Silva EG; Pinto K
Ann Diagn Pathol; 2013 Jun; 17(3):302-4. PubMed ID: 22921726
[TBL] [Abstract][Full Text] [Related]
13. Lymphatic spread among women with primary peritoneal carcinoma.
Eltabbakh GH; Mount SL
J Surg Oncol; 2002 Nov; 81(3):126-31. PubMed ID: 12407724
[TBL] [Abstract][Full Text] [Related]
14. Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study.
Barda G; Menczer J; Chetrit A; Lubin F; Beck D; Piura B; Glezerman M; Modan B; Sadetzki S;
Am J Obstet Gynecol; 2004 Apr; 190(4):1039-45. PubMed ID: 15118638
[TBL] [Abstract][Full Text] [Related]
15. Primary peritoneal serous papillary carcinoma: clinical and laboratory characteristics.
Iavazzo C; Vorgias G; Katsoulis M; Kalinoglou N; Dertimas V; Akrivos T
Arch Gynecol Obstet; 2008 Jul; 278(1):53-6. PubMed ID: 18488238
[TBL] [Abstract][Full Text] [Related]
16. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data.
Vang R; Shih IeM; Salani R; Sugar E; Ayhan A; Kurman RJ
Am J Surg Pathol; 2008 Nov; 32(11):1667-74. PubMed ID: 18769340
[TBL] [Abstract][Full Text] [Related]
17. Grade 1 peritoneal serous carcinomas: a report of 14 cases and comparison with 7 peritoneal serous psammocarcinomas and 19 peritoneal serous borderline tumors.
Weir MM; Bell DA; Young RH
Am J Surg Pathol; 1998 Jul; 22(7):849-62. PubMed ID: 9669347
[TBL] [Abstract][Full Text] [Related]
18. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
19. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
[TBL] [Abstract][Full Text] [Related]
20. Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.
Gao B; Lindemann K; Anderson L; Fereday S; Hung J; Alsop K; Tothill RW; Gebski V; Kennedy C; Balleine RL; ; Harnett PR; Bowtell DD; DeFazio A
Gynecol Oncol; 2016 Sep; 142(3):458-64. PubMed ID: 27444035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
